Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
- PMID: 36679938
- PMCID: PMC9865338
- DOI: 10.3390/vaccines11010093
Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
Abstract
Background: In May 2021, there was an incident regarding giving patients AstraZeneca vaccines stored improperly. They were stored at room temperature (21 degrees centigrade) for 18 h, 12 h longer than the producer recommends. Aim of the study: The paper aims to contribute to the body of knowledge concerning the efficacy and safety of the ChAdOx1-S (AstraZeneca) vaccine concerning the requirements for cold supply chain specification. Patients and methods: Improperly stored vaccines were given to 44 patients, and 39 of them decided to take part in the study. The Control group consisted of 56 people vaccinated on the same days by the same medical teams, using properly stored medicines. Results: The concentration of anti-S1 SARS-CoV-2 Spike protein IgG antibodies did not differ significantly between the groups. Examined group median 70 kU/L (20;100). Control group median 66 kU/L (32.75;100), p = 0.751. We did not observe any COVID-19 infections in either the control or examined group for half a year after the incident. People from each group reported that local and systemic adverse events occurred directly after the first and second doses. In the control group, one case of spontaneously subsiding face edema and joint pain was observed. There were no severe or fatal adverse events. There were no significant differences between the groups, besides the fatigue, after the second dose. Conclusion: AstraZeneca vaccine ChAdOx1-S stored at 21 degrees centigrade for 18 h before vaccination has the same safety profile (p < 0.05) and the same efficacy (p < 0.05) as the vaccines stored in conditions recommended by the producer.
Keywords: COVID-19 vaccination; ChAdOx1-S (AstraZeneca) vaccine; cold supply chain; vaccine efficacy; vaccine safety.
Conflict of interest statement
Authors have no conflict of interest to declare.
Figures
Similar articles
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.Lancet. 2022 Jun 11;399(10342):2212-2225. doi: 10.1016/S0140-6736(22)00770-X. Lancet. 2022. PMID: 35691324 Free PMC article. Clinical Trial.
-
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.Lancet Respir Med. 2021 Nov;9(11):1255-1265. doi: 10.1016/S2213-2600(21)00357-X. Epub 2021 Aug 13. Lancet Respir Med. 2021. PMID: 34391547 Free PMC article.
-
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.Lancet Infect Dis. 2022 Dec;22(12):1716-1727. doi: 10.1016/S1473-3099(22)00502-3. Epub 2022 Sep 5. Lancet Infect Dis. 2022. PMID: 36075233 Free PMC article. Clinical Trial.
-
Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.J Korean Med Sci. 2021 Nov 29;36(46):e311. doi: 10.3346/jkms.2021.36.e311. J Korean Med Sci. 2021. PMID: 34845875 Free PMC article.
-
MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.J Neurol. 2022 Oct;269(10):5198-5212. doi: 10.1007/s00415-022-11194-9. Epub 2022 Jun 23. J Neurol. 2022. PMID: 35737110 Free PMC article. Review.
References
-
- Wang X. Safety and Efficacy of the BNT162b2 MRNA COVID-19 Vaccine. N. Engl. J. Med. 2021;384:1577–1578. - PubMed
-
- Meo S.A., Bukhari I.A., Akram J., Meo A.S., Klonoff D.C. COVID-19 Vaccines: Comparison of Biological, Pharmacological Characteristics and Adverse Effects of Pfizer/BioNTech and Moderna Vaccines. Eur. Rev. Med. Pharmacol. Sci. 2021;25:1663–1669. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous